YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$14.71 USD
-0.13 (-0.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.68 -0.03 (-0.20%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
YMAB 14.71 -0.13(-0.88%)
Will YMAB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for YMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for YMAB
New Strong Buy Stocks for April 19th
New Strong Buy Stocks for April 17th
YMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
Other News for YMAB
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
Y-mAbs to Present at 2024 ASCO Annual Meeting
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition
Y-mAbs Therapeutics says CFO Kruse will resign from his role